卡介苗接种后发生感染的可能原因研究现况

doi:10.3969/j.issn.1000-6621.2020.08.017

摘要/Abstract

摘要：

卡介苗是用于预防结核病的减毒活菌疫苗。虽然卡介苗被认为是最安全的疫苗之一,但仍会出现一些不良反应,其中最严重的是全身播散性卡介苗感染。虽然卡介苗相关感染的发病率低,但预后较差,严重者可致死。因此,加强对卡介苗接种后发生相关感染的认识,特别是对其发病原因的研究,有助于为卡介苗接种和临床疾病的救治提供帮助。

关键词: 结核, 肺, 卡介苗, 接种, 分枝杆菌感染, 先天免疫缺陷病, 孟德尔遗传易感分枝杆菌病

Abstract:

Bacillus Calmette-Guérin (BCG) is an attenuated live bacterial vaccine used for prevention of tuberculosis. Although BCG is proven to be one of the safest vaccines, there are still some adverse reactions. The most severe complication is systemically disseminated BCG infection. Although incidence of BCG-related infections is low, the prognosis is poor and severe cases can be fatal. Therefore, strengthening the understanding of possible causes of BCG-related infections is important for improved BCG vaccination and clinical treatment of these infections.

Key words: Tuberculosis, pulmonary, BCG vaccine, Vaccination, Mycobacterium infections, Primary immunodeficiency disease, Mendelian susceptibility to mycobacterial disease

陈柠, 孙琳, 申阿东, 何秋水. 卡介苗接种后发生感染的可能原因研究现况[J]. 中国防痨杂志, 2020, 42(8): 869-873. doi: 10.3969/j.issn.1000-6621.2020.08.017

CHEN Ning, SUN Lin, SHEN A-dong, HE Qiu-shui. Possible causes of infection after BCG vaccination[J]. Chinese Journal of Antituberculosis, 2020, 42(8): 869-873. doi: 10.3969/j.issn.1000-6621.2020.08.017

图/表 1

表1

参考文献 57

[1]	Peck M, Gacic-Dobo M, Diallo MS, et al. Global Routine Vaccination Coverage, 2018. MMWR Morb Mortal Wkly Rep, 2019,68(42):937-942. doi: 10.15585/mmwr.mm6842a1. doi: 10.15585/mmwr.mm6842a1 URL pmid: 31647786
[2]	World Health Organization. BCG Vaccine: WHO Position Paper, February 2018-Recommendations. Vaccine, 2018,36(24):3408-3410. doi: 10.1016/j.vaccine.2018.03.009. doi: 10.1016/j.vaccine.2018.03.009 URL pmid: 29609965
[3]	Düppre NC, Camacho LA, da Cunha SS, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg, 2008,102(7):631-638. doi: 10.1016/j.trstmh.2008.04.015. doi: 10.1016/j.trstmh.2008.04.015 URL pmid: 18514242
[4]	Portaels F, Aguiar J, Debacker M, et al. Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease. Infect Immun, 2004,72(1):62-65. doi: 10.1128/iai.72.1.62-65.2004. doi: 10.1128/iai.72.1.62-65.2004 URL pmid: 14688081
[5]	Curtis N, Sparrow A, Ghebreyesus TA, et al. Considering BCG vaccination to reduce the impact of COVID-19. Lancet, 2020,395(10236):1545-1546. doi: 10.1016/S0140-6736(20)31025-4. doi: 10.1016/S0140-6736(20)31025-4 URL pmid: 32359402
[6]	Barkai G, Somech R, Stauber T, et al. Bacille Calmette-Guerin (BCG) complications in children with severe combined immunodeficiency (SCID). Infect Dis (Lond), 2019,51(8):585-592. doi: 10.1080/23744235.2019.1628354.
[7]	Fekrvand S, Yazdani R, Olbrich P, et al. Primary Immunodeficiency Diseases and Bacillus Calmette-Guérin (BCG)-Vaccine-Derived Complications: A Systematic Review. J Allergy Clin Immunol Pract, 2020,8(4):1371-1386. doi: 10.1016/j.jaip.2020.01.038. doi: 10.1016/j.jaip.2020.01.038 URL pmid: 32006723
[8]	Hassanzad M, Valinejadi A, Darougar S, et al. Disseminated Bacille Calmette-Guérin infection at a glance: a mini review of the literature. Adv Respir Med, 2019,87(4):239-242. doi: 10.5603/ARM.2019.0040. doi: 10.5603/ARM.2019.0040 URL pmid: 31476012
[9]	Li T, Zhou X, Ling Y, et al. Genetic and Clinical Profiles of Disseminated Bacillus Calmette-Guérin Disease and Chronic Granulomatous Disease in China. Front Immunol, 2019,10:73. doi: 10.3389/fimmu.2019.00073. doi: 10.3389/fimmu.2019.00073 URL pmid: 30761141
[10]	Wu W, Liu D, Nuorti JP, et al. Deaths reported to national surveillance for adverse events following immunization in China, 2010—2015. Vaccine, 2019,37(9):1182-1187. doi: 10.1016/j.vaccine.2019.01.009. doi: 10.1016/j.vaccine.2019.01.009 URL pmid: 30709723
[11]	Pöyhönen L, Bustamante J, Casanova JL, et al. Life-Threa-tening Infections Due to Live-Attenuated Vaccines: Early Manifestations of Inborn Errors of Immunity. J Clin Immunol, 2019,39(4):376-390. doi: 10.1007/s10875-019-00642-3. doi: 10.1007/s10875-019-00642-3 URL pmid: 31123910
[12]	Casanova JL, Jouanguy E, Lamhamedi S, et al. Immunological conditions of children with BCG disseminated infection. Lancet, 1995,346(8974):581. doi: 10.1016/s0140-6736(95)91421-8. doi: 10.1016/s0140-6736(95)91421-8 URL pmid: 7658805
[13]	Marciano BE, Huang CY, Joshi G, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol, 2014,133(4):1134-1141. doi: 10.1016/j.jaci.2014.02.028. doi: 10.1016/j.jaci.2014.02.028 URL pmid: 24679470
[14]	Roos D. Chronic granulomatous disease. Br Med Bull, 2016,118(1):50-63. doi: 10.1093/bmb/ldw009. doi: 10.1093/bmb/ldw009 URL pmid: 26983962
[15]	Ying W, Sun J, Liu D, et al. Clinical characteristics and immunogenetics of BCGosis/BCGitis in Chinese children: a 6 year follow-up study. PLoS One, 2014,9(4):e94485. doi: 10.1371/journal.pone.0094485. doi: 10.1371/journal.pone.0094485 URL pmid: 24722620
[16]	Zhou Q, Hui X, Ying W, et al. A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004—2017). J Clin Immunol, 2018,38(3):260-272. doi: 10.1007/s10875-018-0486-y. doi: 10.1007/s10875-018-0486-y URL pmid: 29560547
[17]	Conti F, Lugo-Reyes SO, Blancas Galicia L, et al. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol, 2016,138(1):241-248. doi: 10.1016/j.jaci.2015.11.041. doi: 10.1016/j.jaci.2015.11.041 URL pmid: 26936803
[18]	Baba LA, Ailal F, El Hafidi N, et al. Chronic granulomatous disease in Morocco: genetic, immunological, and clinical features of 12 patients from 10 kindreds. J Clin Immunol, 2014,34(4):452-458. doi: 10.1007/s10875-014-9997-3. doi: 10.1007/s10875-014-9997-3 URL
[19]	Movahedi Z, Norouzi S, Mamishi S, et al. BCGiosis as a pre-senting feature of a child with chronic granulomatous disease. Braz J Infect Dis, 2011,15(1):83-86. doi: 10.1016/s1413-8670(11)70146-5.
[20]	Kawashima H, Hasegawa D, Nakamura M, et al. Hazards of early BCG vaccination: BCGitis in a patient with chronic granulo-matous disease. Pediatr Int, 2007,49(3):418-419. doi: 10.1111/j.1442-200X.2007.02383.x. doi: 10.1111/j.1442-200X.2007.02383.x URL pmid: 17532851
[21]	Al-Hammadi S, Alsuwaidi AR, Alshamsi ET, et al. Disseminated Bacillus Calmette-Guérin (BCG) infections in infants with immunodeficiency. BMC Res Notes, 2017,10(1):177. doi: 10.1186/s13104-017-2499-7. doi: 10.1186/s13104-017-2499-7 URL pmid: 28476145
[22]	Picard C, Bobby Gaspar H, Al-Herz W, et al. International Union of Immunological Societies: 2017 Primary Immunodeficiency Diseases Committee Report on Inborn Errors of Immunity. J Clin Immunol, 2018,38(1):96-128. doi: 10.1007/s10875-017-0464-9. doi: 10.1007/s10875-017-0464-9 URL pmid: 29226302
[23]	Pasic S, Lilic D, Pejnovic N, et al. Disseminated Bacillus Calmette-Guérin infection in a girl with hyperimmunoglobulin E syndrome. Acta Paediatr, 1998,87(6):702-704. doi: 10.1080/080352598750014166. doi: 10.1080/080352598750014166 URL pmid: 9686668
[24]	Bustamante J. Mendelian susceptibility to mycobacterial di-sease: recent discoveries. Hum Genet, 2020,139(6/7):993-1000. doi: 10.1007/s00439-020-02120-y. doi: 10.1007/s00439-020-02120-y URL
[25]	Rosain J, Kong XF, Martinez-Barricarte R, et al. Mendelian susceptibility to mycobacterial disease: 2014—2018 update. Immunol Cell Biol, 2019,97(4):360-367. doi: 10.1111/imcb.12210. doi: 10.1111/imcb.12210 URL pmid: 30264912
[26]	Picard C, Fieschi C, Altare F, et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am J Hum Genet, 2002,70(2):336-348. doi: 10.1086/338625. doi: 10.1086/338625 URL pmid: 11753820
[27]	Alodayani AN, Al-Otaibi AM, Deswarte C, et al. Mendelian Susceptibility to Mycobacterial Disease Caused by a Novel Founder IL12B Mutation in Saudi Arabia. J Clin Immunol, 2018,38(3):278-282. doi: 10.1007/s10875-018-0490-2. doi: 10.1007/s10875-018-0490-2 URL pmid: 29589181
[28]	Kong XF, Martinez-Barricarte R, Kennedy J, et al. Disruption of an antimycobacterial circuit between dendritic and helper T cells in human SPPL2a deficiency. Nat Immunol, 2018,19(9):973-985. doi: 10.1038/s41590-018-0178-z. doi: 10.1038/s41590-018-0178-z URL pmid: 30127434
[29]	Martínez-Barricarte R, Markle JG, Ma CS, et al. Human IFN-γ immunity to mycobacteria is governed by both IL-12 and IL-23. Sci Immunol, 2018,3(30):eaau6759. doi: 10.1126/sciimmunol.aau6759. doi: 10.1126/sciimmunol.aau6759 URL pmid: 30578351
[30]	Sasaki Y, Nomura A, Kusuhara K, et al. Genetic basis of patients with bacille Calmette-Guérin osteomyelitis in Japan: identification of dominant partial interferon-gamma receptor 1 deficiency as a predominant type. J Infect Dis, 2002,185(5):706-709. doi: 10.1086/339011. doi: 10.1086/339011 URL pmid: 11865431
[31]	Fieschi C, Dupuis S, Catherinot E, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med, 2003,197(4):527-535. doi: 10.1084/jem.20021769. doi: 10.1084/jem.20021769 URL pmid: 12591909
[32]	Lichtenauer-Kaligis EG, de Boer T, Verreck FA, et al. Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. Eur J Immunol, 2003,33(1):59-69. doi: 10.1002/immu.200390008. doi: 10.1002/immu.200390008 URL pmid: 12594833
[33]	Newport M, Levin M, Roesler J, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet, 2004,364(9451):2113-2121. doi: 10.1016/S0140-6736(04)17552-1. doi: 10.1016/S0140-6736(04)17552-1 URL pmid: 15589309
[34]	Chapgier A, Boisson-Dupuis S, Jouanguy E, et al. Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet, 2006,2(8):e131. doi: 10.1371/journal.pgen.0020131. doi: 10.1371/journal.pgen.0020131 URL pmid: 16934001
[35]	Filipe-Santos O, Bustamante J, Haverkamp MH, et al. X-linked susceptibility to mycobacteria is caused by mutations in NEMO impairing CD40-dependent IL-12 production. J Exp Med, 2006,203(7):1745-1759. doi: 10.1084/jem.20060085. doi: 10.1084/jem.20060085 URL pmid: 16818673
[36]	de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore), 2010,89(6):381-402. doi: 10.1097/MD.0b013e3181fdd832. doi: 10.1097/MD.0b013e3181fdd832 URL
[37]	Sologuren I, Boisson-Dupuis S, Pestano J, et al. Partial recessive IFN-γR1 deficiency: genetic, immunological and clinical features of 14 patients from 11 kindreds. Hum Mol Genet, 2011,20(8):1509-1523. doi: 10.1093/hmg/ddr029. doi: 10.1093/hmg/ddr029 URL pmid: 21266457
[38]	Bustamante J, Arias AA, Vogt G, et al. Germline CYBB mutations that selectively affect macrophages in kindreds with X-linked predisposition to tuberculous mycobacterial disease. Nat Immunol, 2011,12(3):213-221. doi: 10.1038/ni.1992. doi: 10.1038/ni.1992 URL pmid: 21278736
[39]	Hambleton S, Salem S, Bustamante J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med, 2011,365(2):127-138. doi: 10.1056/NEJMoa1100066. doi: 10.1056/NEJMoa1100066 URL pmid: 21524210
[40]	Bogunovic D, Byun M, Durfee LA, et al. Mycobacterial disease and impaired IFN-γ immunity in humans with inherited ISG15 deficiency. Science, 2012,337(6102):1684-1688. doi: 10.1126/science.1224026. doi: 10.1126/science.1224026 URL pmid: 22859821
[41]	Prando C, Samarina A, Bustamante J, et al. Inherited IL-12p40 deficiency: genetic, immunologic, and clinical features of 49 patients from 30 kindreds. Medicine (Baltimore), 2013,92(2):109-122. doi: 10.1097/MD.0b013e31828a01f9. doi: 10.1097/MD.0b013e31828a01f9 URL
[42]	Kong XF, Vogt G, Itan Y, et al. Haploinsufficiency at the human IFNGR2 locus contributes to mycobacterial disease. Hum Mol Genet, 2013,22(4):769-781. doi: 10.1093/hmg/dds484. doi: 10.1093/hmg/dds484 URL pmid: 23161749
[43]	Kreins AY, Ciancanelli MJ, Okada S, et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J Exp Med, 2015,212(10):1641-1662. doi: 10.1084/jem.20140280. doi: 10.1084/jem.20140280 URL pmid: 26304966
[44]	Okada S, Markle JG, Deenick EK, et al. IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science, 2015,349(6248):606-613. doi: 10.1126/science.aaa4282. doi: 10.1126/science.aaa4282 URL pmid: 26160376
[45]	Eletto D, Burns SO, Angulo I, et al. Biallelic JAK1 mutations in immunodeficient patient with mycobacterial infection. Nat Commun, 2016,7:13992. doi: 10.1038/ncomms13992. doi: 10.1038/ncomms13992 URL pmid: 28008925
[46]	Oleaga-Quintas C, Deswarte C, Moncada-Vélez M, et al. A purely quantitative form of partial recessive IFN-γR2 deficiency caused by mutations of the initiation or second codon. Hum Mol Genet, 2018,27(22):3919-3935. doi: 10.1093/hmg/ddy275. doi: 10.1093/hmg/ddy275 URL pmid: 31222290
[47]	Bhat GJ, Diwan VK, Chintu C, et al. HIV, BCG and TB in children: a case control study in Lusaka, Zambia. J Trop Pediatr, 1993,39(4):219-223. doi: 10.1093/tropej/39.4.219. doi: 10.1093/tropej/39.4.219 URL pmid: 8411315
[48]	Elenga N, Kouakoussui KA, Bonard D, et al. Diagnosed tuberculosis during the follow-up of a cohort of human immunodeficiency virus-infected children in Abidjan, Côte d'Ivoire: ANRS 1278 study. Pediatr Infect Dis J, 2005,24(12):1077-1082. doi: 10.1097/01.inf.0000190008.91534.b7. doi: 10.1097/01.inf.0000190008.91534.b7 URL pmid: 16371869
[49]	Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine, 2007,25(1):14-18. doi: 10.1016/j.vaccine.2006.07.020. doi: 10.1016/j.vaccine.2006.07.020 URL pmid: 16959383
[50]	Armbruster C, Junker W, Vetter N, et al. Disseminated bacille Calmette-Guérin infection in an AIDS patient 30 years after BCG vaccination. J Infect Dis, 1990,162(5):1216. doi: 10.1093/infdis/162.5.1216. doi: 10.1093/infdis/162.5.1216 URL pmid: 2230251
[51]	Marsh BJ, von Reyn CF, Edwards J, et al. The risks and bene-fits of childhood bacille Calmette-Guérin immunization among adults with AIDS. International MAC study groups. AIDS, 1997,11(5):669-672. doi: 10.1097/00002030-199705000-00015. doi: 10.1097/00002030-199705000-00015 URL pmid: 9108949
[52]	World Health Organization. Releve epidemiologique hebdo-madaire. Wkly Epidemiol Rec, 2007,21(82):181-196.
[53]	Anderson EJ, Webb EL, Mawa PA, et al. The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine, 2012,30(12):2083-2089. doi: 10.1016/j.vaccine.2012.01.053. doi: 10.1016/j.vaccine.2012.01.053 URL pmid: 22300718
[54]	Nissen TN, Birk NM, Kjærgaard J, et al. Adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial. Vaccine, 2016,34(22):2477-2482. doi: 10.1016/j.vaccine.2016.03.100. doi: 10.1016/j.vaccine.2016.03.100 URL pmid: 27060379
[55]	Mostaan S, Yazdanpanah B, Moukhah R, et al. Adverse effects of BCG vaccine 1173 P2 in Iran: A meta-analysis. Adv Biomed Res, 2016,5:99. doi: 10.4103/2277-9175.183659. doi: 10.4103/2277-9175.183659 URL pmid: 27376038
[56]	Heiman S, Weil M, Shulman LM, et al. Co-appearance of OPV and BCG vaccine-derived complications in two infants with severe combined immunodeficiency. Immunol Res, 2018,66(3):437-443. doi: 10.1007/s12026-018-9007-6. doi: 10.1007/s12026-018-9007-6 URL pmid: 29804197
[57]	Roxo-Junior P, Silva J, Andrea M, et al. A family history of serious complications due to BCG vaccination is a tool for the early diagnosis of severe primary immunodeficiency. Ital J Pediatr, 2013,39:54. doi: 10.1186/1824-7288-39-54. doi: 10.1186/1824-7288-39-54 URL pmid: 24016734